Cargando…
Author Correction: scRNA-seq in medulloblastoma shows cellular heterogeneity and lineage expansion support resistance to SHH inhibitor therapy
Autores principales: | Ocasio, Jennifer Karin, Babcock, Benjamin, Malawsky, Daniel, Weir, Seth J., Loo, Lipin, Simon, Jeremy M., Zylka, Mark J., Hwang, Duhyeong, Dismuke, Taylor, Sokolsky, Marina, Rosen, Elias P., Vibhakar, Rajeev, Zhang, Jiao, Saulnier, Olivier, Vladoiu, Maria, El-Hamamy, Ibrahim, Stein, Lincoln D., Taylor, Michael D., Smith, Kyle S., Northcott, Paul A., Colaneri, Alejandro, Wilhelmsen, Kirk, Gershon, Timothy R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9135680/ https://www.ncbi.nlm.nih.gov/pubmed/35618754 http://dx.doi.org/10.1038/s41467-022-30824-4 |
Ejemplares similares
-
scRNA-seq in medulloblastoma shows cellular heterogeneity and lineage expansion support resistance to SHH inhibitor therapy
por: Ocasio, Jennifer Karin, et al.
Publicado: (2019) -
Enhancing CDK4/6 inhibitor therapy for medulloblastoma using nanoparticle delivery and scRNA-seq–guided combination with sapanisertib
por: Lim, Chaemin, et al.
Publicado: (2022) -
Cryptic developmental events determine medulloblastoma radiosensitivity and cellular heterogeneity without altering transcriptomic profile
por: Malawsky, Daniel Shiloh, et al.
Publicado: (2021) -
IMMU-14. WAKING THE SLEEPING GIANT: TLR7/8 AGONIST TREATMENT STIMULATES TUMOR-ASSOCIATED MYELOID CELLS FOR MEDULLOBLASTOMA IMMUNOTHERAPY
por: Pauneto, Coral Alicea, et al.
Publicado: (2023) -
MEDB-56. POx NPs mediated delivery of (TLR7/8) agonist resiquimod improves treatment outcomes in SHH medulloblastoma by targeting tumor associated macrophages
por: Hwang, Duhyeong, et al.
Publicado: (2022)